ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS

Tomcik M, Trinh MT, Trinh-Minh T, TRAN MANH C, Storkanova H, Storkanova L, Senolt L, Klingelhofer J, Hussain RI, Hallen J, Distler J (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

Series: Systemic sclerosis, myositis - etiology, pathogenesis and animal models

City/Town: LONDON

Pages Range: 150-150

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2021-eular.1968

Authors with CRIS profile

Minh Thuong Trinh Department of Medicine 3 – Rheumatology and Immunology CUONG TRAN MANH Professur für Neurobiologie Jörg Distler Professur für Molekulare Mechanismen der Organfibrose

Involved external institutions

Univerzita Karlova v Praze / Charles University in Prague CZ Czech Republic (CZ)

How to cite

APA:

Tomcik, M., Trinh, M.T., Trinh-Minh, T., TRAN MANH, C., Storkanova, H., Storkanova, L.,... Distler, J. (2021). ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS. In ANNALS OF THE RHEUMATIC DISEASES (pp. 150-150). LONDON: BMJ PUBLISHING GROUP.

MLA:

Tomcik, M., et al. "ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2021. 150-150.

BibTeX: Download